{
    "clinical_study": {
        "@rank": "61931", 
        "acronym": "Convince", 
        "arm_group": [
            {
                "arm_group_label": "Icotinib", 
                "arm_group_type": "Experimental", 
                "description": "Icotinib 125mg is administered orally three times per day."
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare icotinib with induction and maintenance chemotherapy\n      in the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with\n      EGFR mutation."
        }, 
        "brief_title": "Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to evaluate the efficacy and safety of icotinib and  pemetrexed-based\n      first-line induction and maintenance chemotherapy in advanced lung adenocarcinoma with\n      EGFR-mutation\uff0cprimary endpoint is progress-free survival\uff0csecond endpoints include overall\n      survival, time to progression, and so on."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.\n\n          -  Positive EGFR Mutation.\n\n          -  No previous systemic anticancer therapy.\n\n          -  Measurable lesion according to RECIST with at least one measurable lesion not\n             previously irradiated, unless disease progression has been documented at that site.\n\n          -  Provision of written informed consent.\n\n        Exclusion Criteria:\n\n          -  Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or\n             small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.\n\n          -  Evidence of clinically active Interstitial Lung Diseases (Patients with chronic,\n             stable, radiographic changes who are asymptomatic need not be excluded).\n\n          -  Known severe hypersensitivity to icotinib or any of the excipients of this product.\n\n          -  Evidence of any other significant clinical disorder or laboratory finding that makes\n             it undesirable for the subject to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "270", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719536", 
            "org_study_id": "BD-IC-IV36"
        }, 
        "intervention": [
            {
                "arm_group_label": "Icotinib", 
                "description": "Icotinib: 125 mg is administered orally three times per day.", 
                "intervention_name": "Icotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BPI-2009", 
                    "Conmana"
                ]
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "description": "First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": "ALIMTA"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pemetrexed"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hefei", 
                        "country": "China", 
                        "state": "Anhui", 
                        "zip": "230022"
                    }, 
                    "name": "The First Affiliated Hospital of Anhui Medical Univercity"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "101149"
                    }, 
                    "name": "Beijing Hospital for Chest Tumors & Tuberculosis Diseases"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100853"
                    }, 
                    "name": "Chinese People's Liberation Army (PLA) General Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400037"
                    }, 
                    "name": "Xinqiao Hospital, The Third Military Medical University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510120"
                    }, 
                    "name": "The First Affiliated Hospital Of Guangzhou Medical Collage"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510515"
                    }, 
                    "name": "Nanfang Hospital, Southern Medical University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ding Cuimin, M.D.", 
                    "phone": "0086-13933083069"
                }, 
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China", 
                        "state": "Hebei", 
                        "zip": "050011"
                    }, 
                    "name": "Hebei Provincal Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Ding Cuimin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Chen Gongyan, M.D", 
                    "phone": "0086-13313636333"
                }, 
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang", 
                        "zip": "110001"
                    }, 
                    "name": "Harbin Medical Univercity Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Chen Gongyan, M.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ma Zhiyong, M.D.", 
                    "phone": "0086-13938239725"
                }, 
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "state": "Henan", 
                        "zip": "450003"
                    }, 
                    "name": "Henan Provincal Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Ma Zhiyong, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "Jiangsu Provincal Tumor Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210009"
                    }, 
                    "name": "Jiangsu Cancer Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Li Wei, M.D", 
                    "phone": "0086-13756661267"
                }, 
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin", 
                        "zip": "130021"
                    }, 
                    "name": "The First Bethune Hospital of Jilin Univercity"
                }, 
                "investigator": {
                    "last_name": "Li Wei, M.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liu Yunpeng, M.D.", 
                    "phone": "0086-13898865122"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110001"
                    }, 
                    "name": "The First Hospital of China Medical University"
                }, 
                "investigator": {
                    "last_name": "Liu Yunpeng, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China", 
                        "state": "Shandong", 
                        "zip": "250117"
                    }, 
                    "name": "Shandong Cancer Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200030"
                    }, 
                    "name": "Shanghai Chest Hospital Affiliated to Shanghai Jiaotong Univercity"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200433"
                    }, 
                    "name": "Changhai Hospital, The Second Military Medical University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200032"
                    }, 
                    "name": "Zhongshan Hospital Affiliated to Fudan Univercity"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ren Xinling, M.D.", 
                    "phone": "0086-13891918331"
                }, 
                "facility": {
                    "address": {
                        "city": "Xian", 
                        "country": "China", 
                        "state": "Shanxi", 
                        "zip": "710032"
                    }, 
                    "name": "Xijing Hospital"
                }, 
                "investigator": {
                    "last_name": "Ren Xinling, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yu Ping, M.D.", 
                    "phone": "0086-13881864070"
                }, 
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "Sichuan Provincal Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Yu Ping, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "West China Hospital, Sichuan University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300060"
                    }, 
                    "name": "Tianjin Medical University Cancer Institute and Hospital"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation", 
        "overall_contact": {
            "last_name": "Shi Yuankai, M.D.", 
            "phone": "0086-13701251865"
        }, 
        "overall_official": {
            "affiliation": "Cancer Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Shi Yuankai, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719536"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "20 months"
            }, 
            {
                "description": "Number of participants who achieve complete response or partial response. Either complete response (CR) or partial response (PR) will be evaluated by RECIST, confirmed at least 28 days following the date of the initial response.", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}